AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY

Brief description of study

This study is all about a new treatment called CRG-022. It is designed to help patients with a certain type of cancer called large B-cell lymphoma (LBCL) who did not get better with a previous treatment. The new treatment works by using special cells called CAR T-cells to target a protein called CD22 found on B-cells, which are involved in the cancer. Some patients face a problem where their cancer becomes resistant to the first treatment that is usually focused on CD19, so CRG-022 aims to tackle this problem by going after CD22 instead. The study wants to find out if CRG-022 actually helps patients with LBCL. The study team will do this by seeing how many patients have their cancer shrink or go away partially or completely. They will also make sure that CRG-022 is safe to use and will not make people feel worse. In addition, the study team is going to look at how CRG-022 affects patients' daily lives and check some markers in their blood to understand more about what the treatment does. They are also going to dig deeper into things like the specific characteristics of the cancer and other treatments the patients received previously.


Clinical Study Identifier: s23-00080


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.